康臣藥業(01681.HK):收到SK-09片臨牀試驗批準通知書
格隆匯4月25日丨康臣藥業(01681.HK)發佈公告,公司已收到中國國家藥品監督管理局簽發的有關SK-09片的《藥物臨牀試驗批準通知書》。SK-09片爲一類化學新藥。
根據披露,足細胞損傷相關腎臟疾病是一類以腎小球足細胞損傷爲主要病理改變的腎臟疾病,包括糖尿病腎病、局竈節段性腎小球硬化、微小病變腎病等。患者常因得不到及時有效的治療,最終進展爲終末期腎病(ESRD),對患者本人、家庭及社會醫療造成沉重負擔。目前臨牀上缺乏針對足細胞保護的靶向療法,SK-09片的臨牀研發有望爲腎臟病患者提供更爲精準有效的治療新選擇。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.